amivantamab   Click here for help

GtoPdb Ligand ID: 10505

Synonyms: amivantamab-vmjw | JNJ-61186372 | JNJ-6372 | JNJ61186372 | Rybrevant®
Approved drug
amivantamab is an approved drug (FDA & EMA (2021))
Compound class: Antibody
Comment: Amivantamab (JNJ-61186372) is a bispecific monoclonal that targets EGFR and MET [2,4,7]. Examination of binding by surface plasmon resonance confirms that JNJ-61186372 can bind to EGFR and MET simultaneously [2]. JNJ-61186372 binding inhibits phosphorylation of both of the target receptor tyrosine kinases in vitro. Tackling the tyrosine kinases from outside the cell is hypothesised to override the issue of treatment resistance due to kinase mutations that frequently arise during therapy with intracellulary-acting small molecule kinase inhibitors [3,5-6].
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
Click here for help
Classification Click here for help
Compound class Antibody
Approved drug? Yes (FDA & EMA (2021))
International Nonproprietary Names Click here for help
INN number INN
11030 amivantamab
Synonyms Click here for help
amivantamab-vmjw | JNJ-61186372 | JNJ-6372 | JNJ61186372 | Rybrevant®
Database Links Click here for help
Specialist databases
IMGT/mAb-DB 937
Other databases
GtoPdb PubChem SID 387065587
Search PubMed clinical trials amivantamab
Search PubMed titles amivantamab
Search PubMed titles/abstracts amivantamab